News

Standing up in public for a broader conception of value in healthcare.

1-8 of 59 News

viewpoint 7/12/17

On the Health Affairs Blog: Sachs Provides an Overview of FDA User Fee Reauthorization Bill Rachel Sachs reviews some of the key provisions of the House of Representative's just-released FDA user fee authorization bill, detailing the recent amendments and what's at stake. READ MORE

viewpoint 6/20/17

On the Health Affairs Blog: Sachs Summarizes Recent HELP Committee Meeting: The Elephant in the Room Rachel Sachs provides a summary of the recent Senate Health, Education, Labor & Pensions (HELP) Committee meeting, organized to focus on how the drug delivery system affects what patients pay. Although the meeting began with a focus on pricing, it soon shifted to a partisan rebuke of the planned ACA repeal. READ MORE

viewpoint 6/19/17

On the Health Affairs Blog: Lietzan Examines SCOTUS Ruling on Biosimilars Erica Lietzan breaks down the recent Supreme Court Sandoz v. Amgen ruling, providing perspective on how the ruling will affect the pathway for approval of biosimilars. READ MORE

viewpoint 6/19/17

IVI's Lakdawalla in WSJ: Look to Major League Baseball for Drug Pricing Insight In a new coauthored commentary appearing in The Wall Street Journal, IVI Executive Director Darius Lakdawalla turns to the national pastime to provide a fresh perspective on the issue of drug pricing and the return on investment pharmaceutical companies need to sustain innovation. READ MORE

viewpoint 6/13/17

On the Health Affairs Blog: Sood, Shih, Van Nuys and Goldman's Study Details the Flow of Funds in Pharma's Distribution System Neeraj Sood, Tiffany Shih, Karen Van Nuys and Dana Goldman discuss the findings of their new study, examining the flow of funds in the pharmaceutical distribution system. READ MORE

viewpoint 6/08/17

Jena and Goldman Discuss the Challenges of Value-Based Pricing in STAT News In a new commentary for STAT News, Anupam Jena (part of IVI's scientific advisory group) and Dana Goldman discuss the advantages of value-based pricing, pointing out several of the key challenges that complicate the application of health technology assessments. READ MORE

viewpoint 6/02/17

On the Health Affairs Blog: Light Addresses the Pharma "Free Rider Myth” (in Response To Yu, Helms, and Bach) Donald Light submits a response to Yu, Helms and Bach's recent Health Affairs blog post on the subject of drug pricing. Light argues that, because the commentary by Yu, Helms, and Bach focuses on the excess of US drug pricing over prices in other developed countries, the authors risk promoting the so-called "foreign free-rider myth," relying on a misperception that the US is paying more than their fare share of drug development costs. READ MORE

viewpoint 6/02/17

On the Health Affairs Blog: Grabowski and Manning Respond To A Recent Post by Yu, Helms, and Bach Henry Grabowski and Richard Manning offer a rebuttal to a recent Health Affairs blog post by authors Yu, Helms, and Bach on the subject of drug pricing, arguing the authors’ premise is flawed and suffers from numerous biases and related methodological issues. READ MORE